Takeda, digesting Nycomed, downsizes in Europe and the US

Share this article:
Takeda said it will slash its global workforce by around 2,800 jobs – 700 of those in the US and the rest in Europe – as it absorbs Nycomed and moves toward a more diverse product portfolio.

The cuts, said Takeda, will span R&D, commercial operations and administrative functions, and will involve the “consolidation of a number of sites and functions, including the potential merger or liquidation of subsidiaries mainly in Europe and a reduction of workforce in the United States,” mainly at Takeda Pharmaceuticals North America.

“The combination of Takeda and Nycomed, which we acquired on September 30, 2011, brought together Takeda's strong presence in the Japanese and U.S. markets with the legacy Nycomed business infrastructure in Europe and high-growth emerging markets,” said Yasuchika Hasegawa, president and CEO, Takeda Pharmaceutical Company Limited. “While our combined operations in more than 70 countries are more complementary than overlapping, there are a number of areas where we will need to make changes to ensure efficient and flexible operations moving forward.”

Takeda acquired Nycomed in a €9.6 billion deal last September, giving the Japanese pharma giant a presence in Europe and emerging markets to match its US footprint. The downsizing is expected to save ¥200 billion through 2015, but at a cost of ¥70 billion.

The company said the cuts were necessary as it rebalances its product portfolio from one dominated by mature products like Actos to a broader array of newer therapies. Takeda boasts products in categories including metabolic, gastroenterology, oncology, cardiovascular, CNS, inflammatory and immune, respiratory and pain management.—MA


Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...